臨床試験と日常臨床における関節リウマチ患者背景の比較

DOI 被引用文献1件 参考文献19件
  • 盛田 和紀
    株式会社あすも臨床薬理研究所（東京女子医科大学病院治験管理室駐在）
  • 山岡 寿子
    株式会社あすも臨床薬理研究所（東京女子医科大学病院治験管理室駐在）
  • 岩方 明日香
    株式会社あすも臨床薬理研究所（東京女子医科大学病院治験管理室駐在）
  • 鈴木 健夫
    株式会社あすも臨床薬理研究所（東京女子医科大学病院治験管理室駐在）
  • 近藤 美和
    東京女子医科大学附属膠原病リウマチ痛風センター
  • 谷口 敦夫
    東京女子医科大学附属膠原病リウマチ痛風センター
  • 吉岡 俊正
    東京女子医科大学病院治験管理室
  • 山中 寿
    東京女子医科大学附属膠原病リウマチ痛風センター

書誌事項

タイトル別名
  • Comparison of the Characteristics of Rheumatoid Arthritis Patients in Clinical Trials and Clinical Practice

この論文をさがす

説明

Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease with cartilage destruction and bone erosions. Recently, many randomized controlled trials (RCTs) have shown that biologic response modifiers including tumor necrosis factor (TNF) inhibitors reduce disease activity and prevent tissue destruction. However, the results of RCTs may not be directly applicable to routine clinical practice because of the different situations including patient selection between RCTs and clinical practice, although the differences in patients' characteristics between RCTs and clinical practice have not been investigated in Japanese. In this study, we compared the demographic and disease characteristics of RA patients recruited in RCTs and those encountered in routine clinical practice.<BR> We selected 52 patients who participated in RCTs of biologics or an anti-rheumatic drug that has been demonstrated to have comparable efficacy to biologics. As the comparator arm, 513 patients who were treated with TNF inhibitors (infliximab, etanercept, and adalimumab) or an IL-6 inhibitor (tocilizumab) in the outpatient clinic of Institute of Rheumatology, Tokyo Women's Medical University were selected. Demographic characteristics of the patients were not substantially different between two groups.In the analysis of disease characteristics, the disease severity assessed by disease activity score (DAS 28) and modified Health Assessment Questionnaire was not different between two groups. However, the proportion of patients treated with ≥7.5 mg/day prednisolone was significantly higher in RCTs than in routine clinical practice. Methotrexate dose was significantly higher in routine clinical practice than in RCTs. These results may reflect the differences in disease characteristics including comorbidities between patients recruited in clinical trials and those encountered in routine clinical practice.

収録刊行物

  • 臨床薬理

    臨床薬理 42 (3), 111-115, 2011

    一般社団法人 日本臨床薬理学会

被引用文献 (1)*注記

もっと見る

参考文献 (19)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ